BPG is committed to discovery and dissemination of knowledge
Featured Articles
7/24/2024 2:33:02 PM | Browse: 508 | Download: 815
 |
Received |
|
2024-04-16 18:12 |
|
Peer-Review Started |
|
2024-04-16 18:12 |
|
First Decision by Editorial Office Director |
|
2024-05-11 07:45 |
|
Return for Revision |
|
2024-05-11 07:45 |
|
Revised |
|
2024-05-20 18:19 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-06-05 02:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-06-05 08:04 |
|
Articles in Press |
|
2024-06-05 08:04 |
|
Edit the Manuscript by Language Editor |
|
2024-06-22 17:59 |
|
Typeset the Manuscript |
|
2024-06-28 14:26 |
|
Publish the Manuscript Online |
|
2024-07-24 13:09 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Minireviews |
| Article Title |
Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: Review of efficacy, safety, and outcomes
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Moiud Mohyeldin, Ahmed S Abuelgasim and Ahmed MG Mustafa |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Moiud Mohyeldin, MD, Doctor, Doctor, Staff Physician, Department of Internal Medicine, University Of Medical Sciences and Technology, Ebed Khatim St, Khartoum 11111, Sudan. moiudahmed@gmail.com |
| Key Words |
Peripheral artery disease; Proprotein convertase subtilisin/kexin type 9 inhibitors; Cardiovascular risk reduction; Evolocumab; Alirocumab; Lipid-lowering therapy; Major adverse limb events; Clinical outcomes; Cost-effectiveness; Safety profile |
| Core Tip |
Evolocumab and alirocumab, which belong to the class of proprotein convertase subtilisin/kexin type 9 inhibitors, are effective in reducing cardiovascular events and major adverse limb events in peripheral artery disease patients. Despite their proven benefits, these inhibitors are underutilized in clinical practice, often due to providers’ lack of awareness and their concerns about cost. This highlights the need for further research to assess these inhibitors’ long-term effects and cost-effectiveness for specific patient groups. |
| Publish Date |
2024-07-24 13:09 |
| Citation |
Mohyeldin M, Abuelgasim AS, Mustafa AM. Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: Review of efficacy, safety, and outcomes. World J Cardiol 2024; 16(7): 397-401
|
| URL |
https://www.wjgnet.com/1949-8462/full/v16/i7/397.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v16.i7.397 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
